<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Pan SD</submitter><funding>Swiss National Science Foundation</funding><pagination>588195</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7674855</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Microglia initiates and sustains the inflammatory reaction that drives the pathogenesis of pneumococcal meningitis. The expression of the G-protein cannabinoid receptor type 2 (CB2) in the brain is low, but is upregulated in glial cells during infection. Its activation down-regulates pro-inflammatory processes, driving microglia towards an anti-inflammatory phenotype. CB2 agonists are therefore therapeutic candidates in inflammatory conditions like pneumococcal meningitis. We evaluated the effects of JWH-133, a specific CB2 agonist on microglial cells, inflammation, and damage driven by &lt;i>S. pneumoniae&lt;/i> &lt;i>in vitro&lt;/i> and in experimental pneumococcal meningitis.&lt;h4>Materials/methods&lt;/h4>Primary mixed glial cultures were stimulated with live or heat-inactivated &lt;i>S.</pubmed_abstract><journal>Frontiers in cellular and infection microbiology</journal><pubmed_title>Adjuvant Cannabinoid Receptor Type 2 Agonist Modulates the Polarization of Microglia Towards a Non-Inflammatory Phenotype in Experimental Pneumococcal Meningitis.</pubmed_title><pmcid>PMC7674855</pmcid><funding_grant_id>189136</funding_grant_id><pubmed_authors>Leib SL</pubmed_authors><pubmed_authors>Grandgirard D</pubmed_authors><pubmed_authors>Pan SD</pubmed_authors></additional><is_claimable>false</is_claimable><name>Adjuvant Cannabinoid Receptor Type 2 Agonist Modulates the Polarization of Microglia Towards a Non-Inflammatory Phenotype in Experimental Pneumococcal Meningitis.</name><description>&lt;h4>Background&lt;/h4>Microglia initiates and sustains the inflammatory reaction that drives the pathogenesis of pneumococcal meningitis. The expression of the G-protein cannabinoid receptor type 2 (CB2) in the brain is low, but is upregulated in glial cells during infection. Its activation down-regulates pro-inflammatory processes, driving microglia towards an anti-inflammatory phenotype. CB2 agonists are therefore therapeutic candidates in inflammatory conditions like pneumococcal meningitis. We evaluated the effects of JWH-133, a specific CB2 agonist on microglial cells, inflammation, and damage driven by &lt;i>S. pneumoniae&lt;/i> &lt;i>in vitro&lt;/i> and in experimental pneumococcal meningitis.&lt;h4>Materials/methods&lt;/h4>Primary mixed glial cultures were stimulated with live or heat-inactivated &lt;i>S.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020</publication><modification>2025-04-26T04:19:15.667Z</modification><creation>2021-02-20T02:46:22Z</creation></dates><accession>S-EPMC7674855</accession><cross_references><pubmed>33251159</pubmed><doi>10.3389/fcimb.2020.588195</doi></cross_references></HashMap>